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Several investigators have reported that breast cancer in younger
women, when compared to their older counterparts, exhibits more
aggressive features including larger tumour size, presence of posi-
tive lymph nodes, absence of steroid receptors and a high S phase
fraction (Wenger et al, 1993; Albain et al, 1994; Walker et al,
1996). Furthermore, young age has been shown to be an indepen-
dent predictor of adverse prognosis (de la Rochefordiere et al,
1993; Albain et al, 1994; Bonnier et al, 1995), a finding that has
resulted in speculation that early-onset breast carcinomas may be
of a biologically different origin and therefore should be regarded
as a separate disease (Adami et al, 1986; Host and Lund, 1986;
de la Rochefordiere et al, 1993; Chung et al, 1996).
To date, most studies concerning genetic characterization of
breast cancer have not considered the age distribution of the
studied patient population, hence, knowledge about possible age-
dependent differentials at the molecular level is still scarce.
Accordingly, the present study was undertaken with intent to
investigate and characterize the genetic alterations associated with
breast cancer in younger women. For this purpose, we performed
loss of heterozygosity (LOH) analysis, using nine different highly
polymorphic microsatellite markers located on chromosomes 11,
13 and 17. These were selected to determine the involvement of
several putative tumour suppressor loci previously shown to be
implicated in breast cancer.
On chromosome 11, markers mapping closely or telomeric to
the recently cloned ATM gene (Savitsky et al, 1995) were
included. Individuals who are heterozygous for the ATM locus,
exhibit an increased sensitivity to ionizing radiation and predispo-
sition to breast cancer (Swift et al, 1987, 1991, 1994; Sanford
et al, 1990). Easton et al (1994) estimated that 3.8% of all female
breast cancer cases, and as many as 8% of early-onset cases
(i.e. afflicting women under the age of 40), could be due to
heterozygous mutations in the ATM gene. The role of ATM in the
processes associated with cell cycle control is still unclear,
although Westphal et al (1997) recently suggested that the proteins
expressed by ATM and TP53 might cooperate in apoptosis and
suppression of tumorigenesis.
The markers selected on chromosome 13 are found in close
proximity to the BRCA2 and the RB1 genes. The protein coded by
the BRCA2 gene, has been implied to have a protective role in cell
proliferation (Vaughn et al, 1996), and mutations in the gene
sequence have been reported to be responsible for a large portion
of hereditary breast cancer cases (Wooster et al, 1995; Phelan et al,
1996; Tavtigian et al, 1996). Numerous investigators have shown
that the RB1 gene is frequently heterozygously lost in breast
cancer (Devilee et al, 1991; Andersen et al, 1992; Borg et al,
1992). The RB protein has a significant role in cell proliferation
and is known to be involved in restriction-point control and G1/S
phase transition during the cell cycle (Sherr, 1996).
Various tumour suppressor genes located on chromosome 17 are
involved in tumour development and/or progression of breast
cancer. In the present study, LOH was assessed for a number of
these genes, including TP53, BRCA1 and NME1. The protein
product of TP53 plays a central role in cell proliferation, arresting
the cell cycle in the G1 phase to allow repair of the DNA in
response to DNA damage. The TP53 gene has been shown to be
implicated in the majority of cancer forms (Nigro et al, 1989;
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TP53 mutations in breast cancer has been found to be higher in
young patients (Caleffi et al, 1994). The role of BRCA1 in the cell
cycle has not yet been elucidated, although it has been proposed
that the protein of this gene may be significant for the maintenance
of the integrity of the genome and that it may interact with Rad51
(Scully et al., 1997), which in turn is known to interact with p53
(Stürzbecher et al, 1996). Recently, Jensen et al (1998) demon-
strated that physical interaction between BRCA1 and a novel
ubiquitin hydrolase named BAP1, enhanced BRCA1-mediated
cell growth suppression. Mutations in BRCA1 and BRCA2 are
presumed to underlie the majority of inherited breast cancer cases
(Miki et al, 1994; Szabo et al, 1995). The protein coded by the
NME1 gene has been reported to exhibit metastatic suppression
capabilities (Leone et al, 1991, 1993), and reduced NME1
expression has been demonstrated to be significantly associated
with aggressive tumour behaviour (Bevilacqua et al, 1989;
Hennessy et al, 1991).
MATERIALS AND METHODS
Patients
The study included 102 young female breast cancer patients diag-
nosed in the South-East Sweden Health Care Region, between
1980 and 1993. The patients were between 24 and 36 years of age
at the time of diagnosis, with a median age of 34. Survival data
were available from the Cause of Death Register provided by the
National Board of Health and Welfare. At the final follow-up,
38 patients were reported to be deceased due to breast cancer; the
median follow-up time was 67 months. Tissue samples from
archival material were obtained from the pathology departments
of hospitals in Linköping, Norrköping, Jönköping and Kalmar.
DNA isolation
Tumour sections were selected from routinely stained formalin-
fixed and paraffin-embedded material. In a minority of cases the
tumour sections also contained parts of normal breast parenchyme
which was removed before DNA extraction. Each case was
matched with normal cells from a lymph node that was free of
metastasis. A slightly modified standard procedure (Shibata et al,
1989) was used for extracting the DNA. Paraffin was removed by
repeated extractions with xylene, followed by washing with
decreasing concentrations of ethanol. The tissue was digested with
10 mg ml–1 proteinase K (Boehringer-Mannheim) in a digestion
buffer containing 8 mM Tris–HCl (pH 8.0), 0.8 mM EDTA, 80 mM
sodium chloride and 2% sodium dodecyl sulphate (SDS).
Digestion was carried out at 55°C for 36 h. Remaining enzymes
were inactivated by heating the samples at 95°C for 10 min.
By-products of the enzymatic digestion were removed from the
nucleic acids by extraction with phenol, phenol–chloroform (1:1)
and chloroform. DNA was precipitated by adding 95% (v/v)
ethanol to a final concentration of 65% (v/v) and sodium acetate to
a final concentration of 0.1 M, and then incubating at –70°C for
1 h. The DNA was pelleted by centrifugation at 12 000 g at 0°C
for 1 h and salt residues were subsequently removed by washing
with 70% ethanol. Nucleic acids were repelleted by centrifuging
as above for 5 min and then vacuum-dried and resuspended in
sterile double-distilled water.
LOH analysis
Nine highly polymorphic microsatellite markers were used, mapping
on chromosome arms 11q, 13q, 17p and 17q (Table 1). The estimated
cytogenetic order of these markers was as follows: 11-cen-
D11S1818-D115969-qtr, 13-cen-D13S260-D13S267-D13S263-qtr
and 17ptr-HP53-cen-NM23-H1-D17S855-qtr. Complete sequence
and chromosomal localization for the markers were obtained
from the GDBTM Human Genome Database (online), Johns
Hopkins University, Baltimore, MD, USA, URL: http://gdbwww.
gdb.orgl.
Polymerase chain reaction (PCR) was performed in a total
reaction volume of 22 ml, containing 25–50 ng of genomic DNA,
2m M magnesium chloride, 1 ´ Taq Polymerase buffer solution
(20 mM (NH4)2SO4, 75 mM Tris–HCl (pH 8.5), 0.1% Tween 20),
1 mM of each primer, 0.2 mM of each dNTP and 0.5 u Taq Poly-
merase (SDS/Promega). Annealing conditions were optimized
specifically for each pair of primers (Table 1), but the
denaturation and extension steps were the same for all markers and
were performed at 94°C for 30 s and 72°C for 45 s respectively.
PCR products were confirmed by agarose (2%) gel separation and
ethidium bromide staining and subsequently subjected to radio-
active labelling with PCR by incorporation of a-dATP32. Labelling
conditions were identical to those used for the primary PCR,
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Table 1 Chromosomal localization, average size and frequency of heterozygosity of the nine different markers. Annealing temperatures and corresponding
number of cycles used for PCR amplification are also included
Locus symbol Chromosomal localizationa Size (bp)a Heterozygosity (%)a Annealing temperature (°C) Number of cycles
D11S1818 11q22–23 140–170 70 55 35
D11S969 11q24.1–25 141–149 76 55 40
D11S387 11q25 168–196 85 53 35
D13S260 13q12.3 158–173 78 55 35
D13S267 13q12.3 148–162 69 62/58b 10/30b
D13S263 13q14.1–14.2 145–165 84 55 35
HP53 17p13.1 103–135 90 68c 35c
NM23-H1 17q21.3 ~ 106 NA 55 35
D17S855 17q21 143–155 82 58/54b 20/20b
a Data was extracted from the GDBTM Human Genome Database. b For the D13S267 and D17S855 markers, PCR was performed at two different annealing
temperatures, i.e. 10 cycles at 62°C followed by 30 cycles at 58°C and 20 cycles at 58°C followed by 20 cycles at 54°C respectively. c PCR was performed
using two-step cycles, i.e. the annealing and extension steps were combined to a single elongated step performed at 68°C. NA, not available.except that the number of cycles was decreased to 15. The
different alleles were then separated on a denaturing polyacryl-
amide (6%) gel containing 8 M urea, at 45 W for 2–3 h. Gels were
dried and exposed on X-ray film (Cronex 4, DuPont) using
intensifying screens, for 5–40 h at –70°C. The evaluation of LOH
was made by visual inspection by at least two independent investi-
gators. LOH was considered to have occurred if the signal
intensity of one allele in the tumour DNA was significantly
reduced, in relation to the other allele, when compared to the
signal intensity observed for the alleles in the corresponding
normal DNA.
Statistical analysis
Correlation of allelic losses between pairs of markers was evalu-
ated with the chi-square test. Survival curves were calculated
according to the method of Kaplan and Meier (1958). The log-rank
test was used to assess differences in patient survival between
cases with loss and retention of heterozygosity at the various
markers.
RESULTS
Of the 102 cases, 90 (88%) exhibited LOH for at least one marker;
40 (39%), 48 (47%) and 58 (57%) showed LOH for markers on
chromosomes 11, 13 and 17 respectively (Table 2). Auto-
radiographs showing LOH for the different markers are illustrated
in Figure 1. The intragenic BRCA1 marker D17S855 exhibited the
highest proportion of LOH (63%) on chromosome 17, whereas a
lower incidence was observed at the HP53 and NM23-H1 loci. On
chromosome 13, the highest proportion of allelic losses was found
at the D13S260 marker, which expressed LOH in 44% of the infor-
mative cases. A lower incidence was observed for the D13S263
and D13S267 markers. The frequency of LOH peaked at the
D11S969 and D11S387 markers on chromosome 11, affecting
53% and 48% of the informative cases, respectively, while LOH at
D11S1818 was only observed in 24% of the cases.
Figure 2 shows the pattern of LOH and survival among cases
where data was available for all markers on each chromosome. No
overlapping region of LOH was found for markers on chromo-
some 17, with only one case showing loss at all three markers
(Figure 2A). Two patients expressed LOH at all three markers on
chromosome 13, whereas the remaining cases exhibited only
partial loss with no significant overlap between markers (Figure
2B). An overlapping region of LOH was found on chromosome
Frequent LOH at 11q24.1–q25 in breast cancer 845
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Table 2 Frequency of LOH and frequency of death in cases with LOH and ROH observed for the different markers. The association between LOH and poor
survival was evaluated using the Log-Rank Test
Locus symbol No. of cases with LOH/ No. of deaths with LOH/ No. of deaths with ROH/ Association between LOH 
no. of informative cases (%) no. of cases with LOH (%) no. of cases with ROH (%) and poor survival (P-value)
D11S1818 13/55 (24) 3/13 (23) 22/42 (52) NSa
D11S969 29/55 (53) 12/29 (41) 12/26 (46) NS
D11S387 31/65 (48) 15/31 (48) 8/34 (24) 0.028
D13S260 21/48 (44) 7/21 (33) 6/27 (22) NS
D13S267 10/42 (24) 3/10 (30) 8/32 (25) NS
D13S263 27/79 (34) 12/27 (44) 17/52 (33) NS
HP53 20/47 (43) 7/20 (35) 8/27 (30) NS
NM23-H1 29/64 (45) 14/29 (48) 11/35 (31) NS
D17S855 26/41 (63) 10/26 (38) 7/15 (47) NS
a NS, not statistically significant, i.e. P > 0.05. LOH, loss of heterozygosity; ROH, retention of heterozygosity.
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Figure 1 Examples of autoradiographs showing allelic loss (LOH) for the
nine different markers. For each case, samples containing normal DNA (N)
were loaded adjacent to the matched sample with tumour DNA (T).
Arrowheads indicate alleles with reduced relative intensity11, comprising the D11S969 and D11S387 markers but excluding
the D11S1818 locus (Figure 2C). Among the nine cases exhibiting
LOH at the D11S387 locus but retention of heterozygosity (ROH)
at the D11S969 marker, six (67%) were deceased due to breast
cancer. In cases with loss of one D11S969 allele but retention of
both D11S387 alleles, only two patients out of ten (20%) were
found to be deceased. However, the poorest outcome, eight deaths
in ten cases (80%), was observed among patients with LOH at
both D11S387 and D11S969.
Log-rank test uncovered a statistically significant difference
(P = 0.028, Table 2) in patient survival between the cases with loss
and those with ROH at the D11S387 marker (Figure 3). No such
correlation was found at the adjacent marker D11S969 located
approximately 500 kb centromeric of D11S387, nor at markers on
chromosomes 13 and 17.
Chi-square analysis performed to examine the correlation of
LOH between markers at the different loci, did not unveil any
statistically significant association between any combination of
markers (data not shown).
DISCUSSION
The genetic aetiology of cancer is complex and presumably
proceeds through a series of alterations that affect genes at several
loci on different chromosomes. In breast cancer, a number of these
loci have been identified, including regions on chromosome 11, 13
and 17. The frequencies of LOH observed in the present study
essentially agree with previous reports (Kerangueven et al, 1995;
Nagai et al, 1995; Beckmann et al, 1996; Schmutzler et al, 1996;
Kerangueven et al, 1997; Niederacher et al, 1997), and thus
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Figure 2 Schematic representation of allelic loss in tumours where data was available for all three markers on each chromosome: (A) chromosome 17,
(B) chromosome 13 and (C) chromosome 11. Tumours exhibiting similar pattern of LOH are grouped together. Filled black and open circles represent loss and
retention of heterozygosity, respectively, whereas non-informative tumours are symbolized by filled grey circles. Cases deceased due to breast cancer are
marked with a crossconfirm that genes located in these regions may play an important
role in the pathogenesis of breast cancer in young women.
However, we also obtained data suggesting that a previously
unidentified gene may be involved in the initiation and/or progres-
sion of early-onset breast cancer.
In keeping with several recent investigations performed on
breast cancer cases not selected for young age (Gudmundsson
et al, 1995; Kerangueven et al, 1997; Koreth et al, 1997), we found
a high proportion of allelic losses at the telomere of chromosome
11 (Table 2). The D11S969 and D11S387 markers, located in the
11q24.1–25 region, demonstrated a significant degree of overlap
with a breakpoint towards the more centromeric marker D11S1818
(Figure 2C). These findings provide support for the existence of an
as yet unidentified tumour suppressor gene or genes, approxi-
mately 20 Mb telomeric to ATM, that may be involved in the
tumorigenic process. Furthermore, log-rank analysis of our data
uncovered a statistically significant correlation between LOH at
the D11S387 marker and poor survival, implying that inactivation
of this gene(s) may provoke more aggressive tumour behaviour.
Recently, Montagna et al (1996) found evidence for the existence
of a gene exhibiting sequence homology to the h-PRL-1 gene in
the 11q24–q25 region. Interestingly, the h-PRL-1 gene has been
suggested to play an important role in the control of basic cellular
processes, such as cell growth and proliferation, making the
h-PRL-1 homologue a possible candidate gene.
The proportion of LOH found at the marker for the ATM locus
was less than half that found at the D11S969 and D11S387
markers. Moreover, as shown in Table 2, comparing the propor-
tions of death among cases with LOH and cases with ROH
between the three markers, demonstrated a two- to fourfold
increase in breast cancer-specific death for the telomeric markers.
These findings suggest a less important role for the ATM gene in
early-onset breast cancer than previously postulated. In further
support for our results, Fitzgerald et al (1997) recently conducted a
case-control study and found that ATM mutations were as common
in the control population as in patients with early-onset breast
cancer. In addition, Vorechovsky ´ et al (1996a, 1996b) performed
screening of 38 consecutive breast cancer cases, and subsequently
on a larger population comprising 88 cases, for ATM mutations
and concluded that there was no evidence for an increased number
of heterozygous ATM carriers in the investigated population.
Compared with previous investigations of sporadic breast
cancer cases not selected for age (Nagai et al, 1995; Beckmann et
al, 1996; Kerangueven et al, 1997; Koreth et al, 1997), we
observed a higher incidence of LOH at the D17S855 marker,
which is located intragenic to BRCA1. This could, in part, reflect
the age-dependent distribution of hereditary and non-hereditary
cases, which was likely shifted towards a higher proportion of
hereditary cases in the studied patient population. Marcus et al
(1994) estimated that approximately half of the breast cancer cases
in women under the age of 30 are of hereditary origin. It is gener-
ally recognized that BRCA1 germ-line mutations account for
almost half of the hereditary breast cancer cases (Miki et al, 1994;
Easton et al, 1995), suggesting that the number of hereditary cases
in the present study is probably not sufficient to satisfactorily
explain the high incidence of LOH at this locus. Assuming a
sequence of genetic events following Knudson’s (1971) ‘two-hit’
hypothesis and since somatic mutations in the BRCA1 gene appear
to be an infrequent event (Futreal et al, 1994; Merajver et al, 1995;
Krainer et al, 1997), a plausible interpretation of our findings
could be that the surroundings of the D17S855 marker may
harbour additional gene(s) that could contribute to the develop-
ment and/or progression of early-onset breast cancer. It is impor-
tant to note, however, that the apparent discordance observed in
previous studies between BRCA1 mutations and LOH at the corre-
sponding locus, could imply that BRCA1 may lose its tumour
suppressor function by down-regulation caused by mechanisms
other than structural mutations (Bièche et al, 1997). A recent study
by Sourvinos and Spandidos (1998) confirmed this by demon-
strating a two- to fivefold reduced BRCA1 expression in tumour
specimen as compared to normal tissue. They proposed that the
reduction in mRNA levels could be due to loss of gene copies
(allelic loss), deletion of regulatory elements in the promoter
region of BRCA1 or failure in the transcriptional regulation by
oestrogen receptors.
Considering the findings of several previous studies suggesting
an association between TP53 status and age (Caleffi et al, 1994;
Walker et al, 1996), we anticipated the frequency of LOH at this
locus to be higher than what is usually found in consecutive
sporadic cases. However, the proportion of cases exhibiting LOH
in the present study falls within the range of what has been previ-
ously reported for cases not selected for age (Andersen et al, 1992;
Cornelis et al, 1994; Schmutzler et al, 1996; Kerangueven et al,
1997; Niederacher et al, 1997). Furthermore, we found no associa-
tion between LOH and poor survival, which is somewhat
surprising since Elledge and Allred (1994), in a review of the
related literature, concluded that overexpression of p53 protein as
well as mutations in the TP53 gene, are independent markers for
adverse prognosis in breast cancer. It is important to note though
that these studies analysed TP53 mutations or p53 protein expres-
sion, and not LOH at this locus. Although there are a few studies in
which loss of TP53 has been investigated for prognostic signifi-
cance (Andersen et al, 1992; Nagai et al, 1994; Lizard-Nacol et al,
1997), the small number of cases included in these studies makes it
hazardous to draw any definitive conclusions. It is thus unclear
whether the lack of association between LOH at the TP53 marker
and poor survival noted in these and the present study is of any
underlying biological significance, or if it merely reflects the
Frequent LOH at 11q24.1–q25 in breast cancer 847
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Figure 3 Survival in relation to loss of heterozygosity (LOH) and retention
of heterozygosity (ROH) at the D11S387 locus. Deaths due to other causes
than breast cancer were censored. The difference in survival between the
two groups was statistically significant (P = 0.028)limited number of observations assessed by the statistical tests.
Alternatively, the discordance between the present report and the
review by Elledge and Allred could be explained by the observed
LOH occurring due to alterations in gene(s) other than TP53
residing in the 17p13.1 region.
In conclusion, it appears that one or more previously uniden-
tified genes located in chromosomal band 11q24.1–q25 are
implicated in early-onset breast cancer. Further refinement of the
deleted region and eventually cloning these genes, thus enabling
mutation analysis, may contribute to the understanding and
elucidation of the molecular mechanisms that underlie the
aetiology of breast cancer in young women.
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